ArticleCancer discovery2012

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Ashish Juvekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.